- Dividend Brief
- Posts
- This Pharma Giant Is Quietly Building Its Next Growth Engine
This Pharma Giant Is Quietly Building Its Next Growth Engine
This is a transition story that is starting to look more predictable.
Core strength remains, but the next phase of growth is already coming into focus.

The Wealth Strategy (Sponsored)
His official paycheck? $400,000 a year.
But the real story is somewhere else: As much as $250,000 per month… from a single source.
It’s not real estate.
It’s not the stock market.
So what’s actually producing this level of cash flow — and why are more investors turning to it today?
Discover how to get started for less than $20

Industrials
Caterpillar Just Became a Core Player in a New Global Buildout

Caterpillar (NYSE: CAT) just signaled a major shift in where its future growth is coming from. The company is seeing a surge in demand tied to large-scale infrastructure and power needs, driven by an accelerating global buildout across industries.
The importance goes beyond equipment sales. Caterpillar is becoming a central supplier to projects that require long-term investment, from construction to power systems that support modern infrastructure.
A New Growth Engine Is Taking Over
Caterpillar has always been linked to global construction cycles. The difference now is the scale and consistency of demand coming from new types of projects that require heavy equipment and reliable power solutions.
You get a company no longer tied solely to traditional cycles but connected to long-term structural demand. That changes stability. It brings more visibility into future activity and strengthens the company’s position across multiple sectors.
The Direction Is Locked In
With demand building across key segments, Caterpillar is positioned at the center of a multi-year expansion in infrastructure and energy-related projects. That creates a foundation for sustained activity rather than short bursts of growth.
The role is becoming clearer with every move. You start to recognize Caterpillar as a company tied directly to how the next phase of global development is being built.
CAT currently trades at $899.00 and pays a dividend of $6.04 per share, a yield of 0.67%.

Pharma
AbbVie Is Building Its Future Pipeline Outside Its Walls

AbbVie (NYSE: ABBV) just made a move that highlights how it is thinking about long-term growth. The company has backed RIME Therapeutics through its Biotech Innovators Award, giving the early-stage company funding, infrastructure, and direct access to AbbVie’s scientific leadership.
AbbVie is positioning itself closer to emerging science instead of waiting for breakthroughs to mature elsewhere.
A Different Way to Build the Pipeline
Large pharma companies often rely on internal research or late-stage acquisitions. AbbVie is leaning into a different model, getting involved earlier and helping shape innovation from the ground up.
You start to recognize a company that is extending its reach beyond its own labs. That approach builds optionality. It gives AbbVie exposure to new therapies without committing to full-scale upfront.
The Bigger Direction Is Taking Shape
Moves like this are not isolated. They reflect a broader effort to stay competitive in an industry where innovation cycles are getting faster and more complex. Building relationships with early-stage biotech firms creates a steady flow of new ideas.
The direction is becoming more defined. You begin to see AbbVie as a company investing in ecosystems, not just products, which strengthens its long-term position.
ABBV currently trades at $209 and pays a dividend of $6.92 per share, a yield of 3.30%.

Income Gap (Sponsored)
For years, America’s top banks have quietly generated outsized profits — while everyday savers earn next to nothing.
Now, an income strategist points to a little-known investment with significantly higher long-term return potential — and says it may now be within reach for regular investors.
Click here to learn how it works — and decide if it fits your strategy.

Retail
400 Stores Getting Beauty Advisors Is Not a Trend, It Is a Strategy

Walmart Inc (NYSE: WMT) is putting trained beauty advisors in more than 400 of its U.S. stores by year-end. These are not just shelf stockers. They recommend products, know what is trending on social media, and help customers find the right shade or formula.
Beauty departments are being moved to the front of stores. Displays now highlight products buzzing on TikTok. And 650 locations are being remodeled as part of the rollout.
Chasing the $129 Billion Beauty Market
The U.S. beauty and personal care market is massive and growing. Walmart has been adding premium brands like La Roche Posay and Nude by Nature alongside its everyday staples. Some of these products cost $40 a bottle. That is not the Walmart most people picture.
You walk into Walmart expecting basic shampoo and find a beauty advisor recommending a French pharmacy sunscreen trending online. The experience gap between Walmart and specialty stores has narrowed noticeably.
This Spreads Beyond Beauty
Walmart is already considering adding specialized electronics experts. Target launched baby concierge services last month. The era of self-service-only retail is ending.
You notice a company this large investing in human expertise at the exact moment everyone else bets on AI replacing people, and it tells a specific story. Walmart believes the human touch still sells, and it is putting hundreds of new hires behind that conviction.
WMT currently trades at $132 and pays a dividend of $0.99 per share, a yield of 0.75%.

Dividend Stocks Worth Watching
The Hershey Company (NYSE: HSY) has delivered a solid quarter, with revenue climbing more than 10% as demand for mints, gum, and protein snacks provided an unexpected boost.
What’s interesting here is the suggested shift in consumer behavior. The growing use of GLP-1 weight loss drugs is starting to reshape snacking habits, with consumers moving away from traditional impulse treats and toward functional, premium, or smaller-format options. Hershey is already seeing that play out, with strong growth in Ice Breakers and protein bars.
This creates an interesting positioning shift. While its legacy confectionery business still matters, newer demand drivers tied to health trends and changing consumption patterns are beginning to support growth.
For dividend investors, this is an evolving story. Hershey is tapping into a new tailwind that could reshape its product mix, but the key will be how consistently it can translate that shift into sustained earnings growth. HSY pays a $1.45 dividend, yielding 3.15%.
Stellantis N.V. (NYSE: STLA) and Harley-Davidson, Inc. (NYSE: HOG) are reigniting their partnership across Europe for 2026, bringing together two of the most recognizable lifestyle brands in automotive and motorcycling.
The collaboration will center around a series of major events and rallies across the region, starting with the European Spring Rally in Italy and continuing through Portugal, Austria, and beyond. These gatherings are designed to tap into the strong communities behind both brands, combining shared values of freedom, adventure, and identity.
More than a marketing tie-up, this is a strategic alignment designed to deepen brand loyalty and expand audience engagement through experiential events. Jeep will also use the partnership to showcase its latest models, including the electrified Compass 4xe, positioning itself at the intersection of heritage and modern innovation.
For investors, it highlights how legacy brands are leaning into community-driven experiences and partnerships to stay relevant, reinforce brand equity, and support long-term demand. STLA pays a 68-cent annual dividend, yielding 10.58%, while HOG pays a 19-cent quarterly dividend, yielding 3.07%.
Merck & Co., Inc. (NYSE: MRK) has just reported a constructive quarter, beating on both earnings and revenue as demand for its blockbuster cancer drug Keytruda and newer therapies continued to drive growth. The company also raised its adjusted profit outlook and tightened its full-year revenue guidance, signaling confidence in the underlying business.
The reason this stock is worth watching right now is the strength and evolution of its drug portfolio. Keytruda remains a dominant earnings engine, with strong growth across both early-stage and advanced cancers, while newer treatments like Winrevair are scaling quickly and starting to contribute meaningfully. That combination of established leadership and emerging growth drivers is helping offset upcoming patent risks.
The story is one of transition with momentum. Core products are still delivering, new therapies are gaining traction, and management is guiding with confidence. The opportunity lies in how effectively Merck can convert its pipeline into the next wave of durable earnings. MRK pays an 85-cent dividend, yielding 3.00%.

Dividend Increases
AIG has increased its dividend to 50 cents, up 11.11%. Its new yield is 2.67%.
RTX has lifted its dividend to 73 cents, a rise of 7.35%. Its new yield is 1.66%.
FHI has boosted its dividend to 38 cents, a growth of 11.76%. Its new yield is 2.62%.
SAH has raised its dividend to 41 cents, an increase of 7.89%. Its new yield is 2.08%.
Dividend Decreases
ZGN has cut its dividend to 12 cents, an 11.82% drop. Its new yield is 0.99%.
GSK has trimmed its dividend to 44 cents, a decline of 9.39%. Its new yield is 3.36%.

History Repeating Itself (Sponsored)
On August 15, 1971, Richard Nixon ended the gold standard—changing the value behind every dollar overnight.
Those who acted early positioned themselves ahead of a major shift, while others felt the impact over time.
Today, new discussions around monetary policy are drawing renewed attention from investors.
The 2026 Gold Guide explains what happened—and why it still matters.
Get the free guide now

Poll: What's your ideal "yield on cost" — the dividend yield based on your original purchase price — for a long-term holding? |

Upcoming Dividend Payers
PNC’s ex-dividend date for the forthcoming $1.70 payment is 05/05/26.
CNXC’s ex-dividend date for the forthcoming 36-cent payment is 05/05/26.
LOW’s ex-dividend date for the forthcoming $1.20 payment is 05/06/26.
GGG’s ex-dividend date for the forthcoming 29-cent payment is 05/06/26.

Everything Else
Estée Lauder has confirmed plans to lay off up to 10,000 workers as part of its ongoing restructuring drive, even as organic sales rise.
Colgate-Palmolive has become the latest company to put a price on the operational cost of the conflict in the Middle East, saying it’s facing an estimated $300 million hit in additional raw material and logistics expenses.
Tractor maker John Deere has named Brent Norwood as senior vice president and chief financial officer after two decades at the company.
Mark Zuckerberg has told Meta employees that more job cuts could be coming down the line due to increased capital spending and a pivot into AI.

That’s all for today’s edition of the Dividend Brief.
Thanks for reading, and if you have any feedback or dividend stocks you want me to take a look at, just reply to this email!
—Noah Zelvis
DividendBrief.com


